The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
Abstract
Cancer is a leading cause of premature human death and commands considerable research attention. Apoptosis (type 1 programmed cell death) is critical in maintaining tissue homeostasis in metazoan organisms, and its dysregulation underpins the initiation and progression of cancer. Conventional chemotherapy and radiotherapy can induce apoptosis as a secondary consequence of inflicting cell damage. However, more direct and selective strategies to manipulate the apoptotic process in cancer cells are emerging as potential therapeutic tools. Genetic and biochemical understanding of the cellular signaling mechanisms that control apoptosis has increased substantially during the last decade. These advances provide a strong scientific framework for developing several types of targeted proapoptotic anticancer therapies. One promising class of agents is the proapoptotic receptor agonists. Of these, recombinant human apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (rhApo2L/TRAIL)—an optimized soluble form of an endogenous apoptosis-inducing ligand—is unique in that it activates two related proapoptotic receptors, DR4 and DR5. Preclinical data indicate that rhApo2L/TRAIL can induce apoptosis in a broad range of human cancer cell lines while sparing most normal cell types. In vitro, and in various in vivo tumor xenograft models, rhApo2L/TRAIL exhibits single-agent antitumor activity and/or cooperation with certain conventional and targeted therapies. Preclinical safety studies in nonhuman primates show rhApo2L/TRAIL to be well tolerated. Moreover, early clinical trial data suggest that rhApo2L/TRAIL is generally safe and provide preliminary evidence for potential antitumor activity. Clinical studies are ongoing to assess the safety and efficacy of this novel agent in combination with established anticancer therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Death-receptor activation halts clathrin-dependent endocytosis
Austin, C. D., Lawrence, D. A., Peden, A. A., Varfolomeev, E. E., Tótpál, K., Mazière, A. M. G. L. D., Klumperman, J., Arnott, D. P., Pham, V. C., Scheller, R. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604044103 · Cited by 116
Self-citationRetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Self-citationDanial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
Cancer incidence, mortality and prevalence worldwide
Ferlay, J. (2004) · Medical Entomology and Zoology · Cited by 3,796
Live or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
Identification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Safety and antitumor activity of recombinant soluble Apo2 ligand
Ashkenazi, A., Pai, R. C., Fong, S., Leung, S., Lawrence, D. A., Marsters, S. A., Blackie, C., Chang, L., McMurtrey, A. E., Hebert, A., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6926 · Cited by 2,213
Self-citationDeath and anti-death: tumour resistance to apoptosis
Igney, F. H., & Krammer, P. H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc776 · Cited by 2,075
Metastasis: a question of life or death
Mehlen, P., & Puisieux, A. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1886 · Cited by 1,863
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A., & Ashkenazi, A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.12687 · Cited by 1,793
Self-citationControl of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
Sheridan, J. P., Marsters, S. A., Pitti, R. M., Gurney, A., Skubatch, M., Baldwin, D., Ramakrishnan, L., Gray, C. L., Baker, K., Wood, W. I., et al. (1997) · Science · doi:10.1126/science.277.5327.818 · Cited by 1,664
Self-citationTargeting death and decoy receptors of the tumour-necrosis factor superfamily
Ashkenazi, A. (2002) · Nature Reviews Cancer · doi:10.1038/nrc821 · Cited by 1,360
Self-citationTargeting Apoptosis Pathways in Cancer Therapy
Ghobrial, I. M., Witzig, T. E., & Adjei, A. A. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.3.178 · Cited by 1,330
Lowe, S. W., Cepero, E., & Evan, G. (2004) · Nature · doi:10.1038/nature03098 · Cited by 1,309
Promoting apoptosis as a strategy for cancer drug discovery
Fesik, S. W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1736 · Cited by 1,098
Apo2L/TRAIL-Dependent Recruitment of Endogenous FADD and Caspase-8 to Death Receptors 4 and 5
Kischkel, F. C., Lawrence, D. A., Chuntharapai, A., Schow, P., Kim, K. J., & Ashkenazi, A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80212-5 · Cited by 975
Self-citationApo2L/TRAIL and its death and decoy receptors
LeBlanc, H. N., & Ashkenazi, A. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401187 · Cited by 854
Self-citationJo, M., Kim, T.-H., Seol, D.-W., Esplen, J. E., Dorko, K., Billiar, T. R., & Strom, S. C. (2000) · Nature Medicine · doi:10.1038/75045 · Cited by 843
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
Lawrence, D., Shahrokh, Z., Marsters, S., Achilles, K., Shih, D., Mounho, B., Hillan, K., Totpal, K., DeForge, L., Schow, P., et al. (2001) · Nature Medicine · doi:10.1038/86397 · Cited by 702
Self-citationCaspases: pharmacological manipulation of cell death
Lavrik, I. N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26252 · Cited by 644
Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612
Self-citationTumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity
Ichikawa, K., Liu, W., Zhao, L., Wang, Z., Liu, D., Ohtsuka, T., Zhang, H., Mountz, J. D., Koopman, W. J., Kimberly, R. P., et al. (2001) · Nature Medicine · doi:10.1038/91000 · Cited by 543
Inhibition of Fas death signals by FLIPs
Tschopp, J., Irmler, M., & Thome, M. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80223-9 · Cited by 520
Microtubules, microtubule-interfering agents and apoptosis
Mollinedo, F., & Gajate, C. (2003) · Apoptosis · doi:10.1023/a:1025513106330 · Cited by 477
TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO
Deng, Y., Lin, Y., & Wu, X. (2002) · Genes & Development · doi:10.1101/gad.949602 · Cited by 458
Kelley, S. K., Harris, L. A., Xie, D., DeForge, L., Totpal, K., Bussiere, J., & Fox, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29298-3 · Cited by 445
Hymowitz, S. G., Christinger, H. W., Fuh, G., Ultsch, M., O'Connell, M., Kelley, R. F., Ashkenazi, A., & de Vos, A. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80207-5 · Cited by 435
Self-citationMitsiades, C. S., Treon, S. P., Mitsiades, N., Shima, Y., Richardson, P., Schlossman, R., Hideshima, T., & Anderson, K. C. (2001) · Blood · doi:10.1182/blood.v98.3.795 · Cited by 392
Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim, K., Fisher, M. J., Xu, S., & El‐Deiry, W. S. (2000) · PubMed · Cited by 376
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., DeForge, L., Pai, R., Hymowitz, S. G., & Ashkenazi, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410660200 · Cited by 284
Self-citationA Unique Zinc-Binding Site Revealed by a High-Resolution X-ray Structure of Homotrimeric Apo2L/TRAIL
Hymowitz, S. G., O'Connell, M. P., Ultsch, M. H., Hurst, A., Totpal, K., Ashkenazi, A., de Vos, A. M., & Kelley, R. F. (2000) · Biochemistry · doi:10.1021/bi992242l · Cited by 261
Self-citationGliniak, B., & Le, T. (1999) · PubMed · Cited by 261
Ricci, M. S., Kim, S.-H., Ogi, K., Plastaras, J. P., Ling, J., Wang, W., Jin, Z., Liu, Y. Y., Dicker, D. T., Chiao, P. J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.006 · Cited by 255
Temperature-sensitive Differential Affinity of TRAIL for Its Receptors
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., Mclaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910438199 · Cited by 245
Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL Sensitivity
Ricci, M. S., Jin, Z., Dews, M., Yu, D., Thomas-Tikhonenko, A., Dicker, D. T., & El-Deiry, W. S. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8541-8555.2004 · Cited by 243
Ganten, T. M., Koschny, R., Sykora, J., Schulze-Bergkamen, H., Büchler, P., Haas, T. L., Schader, M. B., Untergasser, A., Stremmel, W., & Walczak, H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2635 · Cited by 217
Isotype-Dependent Inhibition of Tumor Growth In Vivo by Monoclonal Antibodies to Death Receptor 4
Chuntharapai, A., Dodge, K., Grimmer, K., Schroeder, K., Marsters, S. A., Koeppen, H., Ashkenazi, A., & Kim, K. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4891 · Cited by 202
Self-citationNimmanapalli, R., Perkins, C. L., Орландо, М., O'Bryan, E., Nguyen, D. N., & Bhalla, K. N. (2001) · PubMed · Cited by 201
Taxol Induces Caspase-10-dependent Apoptosis
Park, S.-J., Wu, C.-H., Gordon, J. D., Zhong, X., Emami, A., & Safa, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406543200 · Cited by 198
Rowinsky, E. K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2889 · Cited by 197
Naka, T., Sugamura, K., Hylander, B. L., Widmer, M. B., Rustum, Y. M., & Repasky, E. A. (2002) · PubMed · Cited by 190
APO2 ligand: a novel lethal weapon against malignant glioma?
Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A., & Weller, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00409-8 · Cited by 189
Self-citationCysteine 230 Is Essential for the Structure and Activity of the Cytotoxic Ligand TRAIL
Bodmer, J.-L., Meier, P. F., Tschopp, J., & Schneider, P. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909721199 · Cited by 182
Apoptosis, cancer and the p53 tumour suppressor gene
Lee, J. M., & Bernstein, A. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00665797 · Cited by 169
Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway
Wang, Y., Engels, I. H., Knee, D. A., Nasoff, M., Deveraux, Q. L., & Quon, K. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00113-8 · Cited by 161
TRAIL Inhibits Tumor Growth but Is Nontoxic to Human Hepatocytes in Chimeric Mice
Hao, C., Song, J. H., Hsi, B., Lewis, J. T., Song, D. K., Petruk, K. C., Tyrrell, D., & Kneteman, N. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2599 · Cited by 154
Gazitt, Y. (1999) · Leukemia · doi:10.1038/sj.leu.2401501 · Cited by 154
Ozols, R. F., Herbst, R. S., Colson, Y. L., Gralow, J. R., Bonner, J., Curran, W. J., Eisenberg, B. L., Ganz, P. A., Kramer, B. S., Kris, M. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.7030 · Cited by 149
Pollack, I. F., Erff, M., & Ashkenazi, A. (2001) · PubMed · Cited by 137
Self-citationShankar, S., Singh, T. R., & Srivastava, R. K. (2004) · The Prostate · doi:10.1002/pros.20069 · Cited by 115
Ray, S., & Almasan, A. (2003) · PubMed · Cited by 115
Hylander, B. L., Pitoniak, R., Penetrante, R. B., Gibbs, J. F., Oktay, D., Cheng, J., & Repasky, E. A. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-22 · Cited by 114
Jin, H., Yang, R., Fong, S., Tótpál, K., Lawrence, D. A., Zheng, Z., Ross, J., Koeppen, H., SCHWALL, R. H., & Ashkenazi, A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0408 · Cited by 113
Self-citationDaniel, D., Yang, B., Lawrence, D. A., Tótpál, K., Balter, I., Lee, W. P., Gogineni, A., Cole, M. J., Yee, S. F., Ross, S., et al. (2007) · Blood · doi:10.1182/blood-2007-02-076075 · Cited by 112
Self-citationAvoiding premature apoptosis of normal epidermal cells
Qin, J., Chaturvedi, V., Bonish, B. K., & Nickoloff, B. J. (2001) · Nature Medicine · doi:10.1038/86401 · Cited by 106
Herbst, R. S., Mendolson, D. S., Ebbinghaus, S., Gordon, M. S., O'Dwyer, P. J., Lieberman, G. S., Ing, J., Kurzrock, R., Novotny, W. F., & Eckhardt, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3013 · Cited by 103
Peták, I., Douglas, L., Tillman, D. M., Vernes, R., & Houghton, J. A. (2000) · PubMed · Cited by 95
Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis
Marini, P., Schmid, A., Jendrossek, V., Faltin, H., Daniel, P. T., Budach, W., & Belka, C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-5 · Cited by 94
Lincz, L. F., Yeh, T.-X., & Spencer, A. G. (2001) · Leukemia · doi:10.1038/sj.leu.2402251 · Cited by 88
Nesterov, A., Nikrad, M. P., Johnson, T. R., & Kraft, A. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2219 · Cited by 80
Drosopoulos, K. G., Roberts, M. L., C̆ermák, L., Sasazuki, T., Shirasawa, S., Anděra, L., & Pintzas, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412483200 · Cited by 80
Ravi, R. K., Jain, A. J., Schulick, R. D., Pham, V., Prouser, T. S., Allen, H. E., Mayer, E.-G., Yu, H., Pardoll, D. M., Ashkenazi, A., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2488 · Cited by 78
Self-citationYee, L., Fanale, M. A., Dimick, K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.8078 · Cited by 68
Ménoret, E., Gomez‐Bougie, P., Geffroy-Luseau, A., Daniels, S. M., Moreau, P., Gouill, S. L., Harousseau, J., Bataille, R., Amiot, M., & Pellat‐Deceunynck, C. (2006) · Blood · doi:10.1182/blood-2005-12-007971 · Cited by 64
Xu, Z., Friess, H., Solioz, M., Aebi, S. P., Korc, M., Kleeff, J. H., & B�chler, M. W. (2001) · International Journal of Cancer · doi:10.1002/ijc.1447 · Cited by 63
Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani, Y., Yoshida, O., Miki, T., & Bonavida, B. (1999) · PubMed · Cited by 59
Trail Receptor-Targeted Therapy
Buchsbaum, D. J., Zhou, T., & LoBuglio, A. F. (2006) · Future Oncology · doi:10.2217/14796694.2.4.493 · Cited by 52
Xiang, H., Fox, J. A., Tótpál, K., Aikawa, M., DuPree, K., Sinicropi, D. V., Lowe, J. R., & Escandón, E. (2002) · Oncogene · doi:10.1038/sj.onc.1205449 · Cited by 51
VanOosten, R. L., Earel, J. K., & Griffith, T. S. (2006) · APOPTOSIS · doi:10.1007/s10495-006-0009-9 · Cited by 47
Papageorgiou, A., Kamat, A. M., Benedict, W. F., Dinney, C. P., & McConkey, D. J. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0474 · Cited by 35
Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma
Ling, J., Herbst, R. S., Mendelson, D. S., Eckhardt, S., O'Dwyer, P. J., Ebbinghaus, S., Osborne, R., Cheu, M., Lieberman, G., & Lum, B. L. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.3047 · Cited by 35
Self-citationCaspase-10 involvement in cytotoxic drug-induced apoptosis of tumor cells
Filomenko, R., Prévotat, L., Rébé, C., Cortier, M., Jeannin, J.-F., Solary, É., & Bettaı̈eb, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209733 · Cited by 34
Mouzakiti, A., & Packham, G. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04424.x · Cited by 27
Pan, Y., Xu, R., Peach, M., Huang, C. Y., Branstetter, D. G., Durbin, B., Herbst, R. S., Eckhardt, G., Mendelson, D. S., & Holland, P. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3535 · Cited by 18
Self-citationInnate Tumor Immune Surveillance
Smyth, M. J., Swann, J. B., & Hayakawa, Y. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-34814-8_7 · Cited by 14
Cited by
Clinical targeting of the TNF and TNFR superfamilies
Croft, M., Benedict, C. A., & Ware, C. F. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3930 · Cited by 456
Herbst, R. S., Eckhardt, S. G., Kurzrock, R., Ebbinghaus, S., O'Dwyer, P. J., Gordon, M. S., Novotny, W., Goldwasser, M. A., Tohnya, T. M., Lum, B. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1991 · Cited by 446
Self-citationDual targeting strategies with bispecific antibodies
Kontermann, R. (2012) · mAbs · doi:10.4161/mabs.4.2.19000 · Cited by 435
Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
Ashkenazi, A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2637 · Cited by 432
Self-citationMitochondria-mediated apoptosis in mammals
Xiong, S., Mu, T., Wang, G., & Jiang, X. (2014) · Protein & Cell · doi:10.1007/s13238-014-0089-1 · Cited by 398
Metadata
- Authors
- Ashkenazi, A., Holland, P., & Eckhardt, S. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-07-20
- Volume
- 26
- Issue
- 21
- Pages
- 3621-3630
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2020439083
- Cited by
- 421
- References
- 76
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.